Merseyside Inter Agency Drug Misuse Database

January – March 2007

Halton DAT

Quarter 4 2006/07

Esther Shepherd, Martin Chandler,
Jim McVeigh

DRAFT REPORT
The final version will be available on the IAD website

www.cph.org.uk/iad

Acknowledgements:
The Authors would like to thank the following for their valuable contributions to the production of this report: Paul Duffy, Adam Marr, Simon Russell and Claire Shaw.
We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts:
Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
Castle House
North Street
L3 2AY

(0151) 231 4531
m.chandler@ljmu.ac.uk

Esther Shepherd
IAD Researcher

(0151) 231 4521
e.shepherd@ljmu.ac.uk

www.cph.org.uk/iad

Contents

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)

Quarter 4 (2006/07)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	9	81.8
Female	2	18.2
Age Group		
Under 18	0	0
18-19	0	0
20-24	1	9.1
25-29	4	36.4
30-34	3	27.3
35-39	2	18.2
40-44	1	9.1
45+	0	0
Total	*11*	*100*

Table 2: Year to Date, by Gender & Age Group

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	**n**	**%**	**n**	**%**	***n***	***%***
Under 18	2	2.7	0	0	2	2.2
18-19	2	2.7	2	11.1	4	4.3
20-24	11	14.9	1	5.6	12	13.0
25-29	19	25.7	4	22.2	23	25.0
30-34	17	23.0	4	22.2	21	22.8
35-39	18	24.3	6	33.3	24	26.1
40-44	4	5.4	1	5.6	5	5.4
45+	1	1.4	0	0	1	1.1
Total	*74*	*100*	*18*	*100*	*92*	*100*

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Crack	3	0
Heroin	11	0
Methadone	2	0

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

PROBATION

Quarter 4 (2006/07)

Introduction

Data is provided by Cheshire Probation Services. Data relates to individuals reported through OASys with a reported substance use problem. Individuals who are on ASROs or similar treatment orders are reported to NDTMS.

NOTE: Probation figures are based on DAT of Residence, NOT DAT of contact as with other datasets.

Table 4: Probation Clients by Gender and Age Group

Gender	n	%
Male	50	87.7
Female	7	12.3
Age Group		
Under 18	0	0
18-19	4	7.0
20-24	10	17.5
25-29	13	22.8
30-34	17	29.8
35-39	8	14.0
40-44	4	7.0
45+	1	1.8
Total	*57*	*100*

Table 5: Year to Date, by Gender & Age Group

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	**n**	**%**	**n**	**%**	***n***	***%***
Under 18	0	0	0	0	0	0
18-19	23	13.2	2	7.4	25	12.4
20-24	45	25.9	4	14.8	49	24.4
25-29	31	17.8	5	18.5	36	17.9
30-34	23	13.2	8	29.6	31	15.4
35-39	20	11.5	3	11.1	23	11.4
40-44	13	7.5	4	14.8	17	8.5
45+	19	10.9	1	3.7	20	10.0
Total	*174*	*100*	*27*	*100*	*201*	*100*

Table 6: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Benzodiazepines	1	0
Cannabis	4	4
Crack	3	3
Heroin	4	2
Methadone	3	0

N.B: Table 6 shows the number of people reporting daily or weekly use of specific drugs. This is to reflect reporting of polydrug use through Probation data. No totals are given as clients can report daily or weekly use of more than one drug and may therefore be double counted between drugs.

ASROs

- 9 ASROs were commenced during Q4 0607
- 8 Individuals commenced ASROs between January– March 2007
- 13 ASROs were terminated during Q4 0607
- 10 individuals had their ASROs' terminated between January– March 2007

SYRINGE EXCHANGE SERVICES

Quarter 4 (2006/07)

Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY SYRINGE EXCHANGE

Table 7: Individuals by Gender

New Clients	n	%
Male	36	97.3
Female	1	2.7
Total	*37*	*100*
All Clients		
Male	168	94.4
Female	10	5.6
Total	*178*	*100*

Table 8: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	4	80.0
Female	1	20.0
Total	*5*	*100*
All Clients		
Male	55	84.6
Female	10	15.4
Total	*65*	*100*

Table 9: Individuals by Age Group

	New Clients		All Clients	
Age Group	n	**%**	n	**%**
Under 18	0	0	0	0
18-19	6	16.2	6	3.4
20-24	11	29.7	37	20.8
25-29	9	24.3	36	20.2
30-34	2	5.4	28	15.7
35-39	5	13.5	36	20.2
40-44	3	8.1	22	12.4
45+	1	2.7	13	7.3
Total	*37*	*100*	*178*	*100*

Table 10: Individuals by Age Group: Steroid Users Omitted

	New Clients		All Clients	
Age Group	n	**%**	n	**%**
Under 18	0	0	0	0
18-19	0	0	0	0
20-24	1	20.0	3	4.6
25-29	0	0	7	10.8
30-34	0	0	13	20.0
35-39	2	40.0	22	33.8
40-44	2	40.0	13	20.0
45+	0	0	7	10.8
Total	*5*	*100*	*65*	*100*

Table 11: Gender by Age Group of Individuals

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0	0	0
18-19	6	3.6	0	0
20-24	37	22.0	0	0
25-29	34	20.2	2	20.0
30-34	26	15.5	2	20.0
35-39	33	19.6	3	30.0
40-44	21	12.5	1	10.0
45+	11	6.5	2	20.0
Total	*168*	*100*	*10*	*100*

Table 12: Gender by Age Group: Steroid Users omitted

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0	0	0
18-19	0	0	0	0
20-24	3	5.5	0	0
25-29	5	9.1	2	20.0
30-34	11	20.0	2	20.0
35-39	19	34.5	3	30.0
40-44	12	21.8	1	10.0
45+	5	9.1	2	20.0
Total	*55*	*100*	*10*	*100*

Table 13: Year to Date, by Gender & Age Group

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	**n**	**%**	**n**	**%**	***n***	***%***
Under 18	1	0.3	0	0	1	0.3
18-19	16	4.3	0	0	16	4.1
20-24	95	25.6	1	5.0	96	24.6
25-29	80	21.6	6	30.0	86	22.0
30-34	71	19.1	4	20.0	75	19.2
35-39	53	14.3	3	15.0	56	14.3
40-44	30	8.1	2	10.0	32	8.2
45+	25	6.7	4	20.0	29	7.4
Total	*371*	*100*	*20*	*100*	*391*	*100*

Table 14: Year to Date, by Gender & Age Group: Steroid Users Omitted

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	**n**	**%**	**n**	**%**	***n***	***%***
Under 18	0	0	0	0	0	0
18-19	1	0.9	0	0	1	0.8
20-24	8	7.5	1	5.0	9	7.1
25-29	16	15.0	6	30.0	22	17.3
30-34	28	26.2	4	20.0	32	25.2
35-39	27	25.2	3	15.0	30	23.6
40-44	16	15.0	2	10.0	18	14.2
45+	11	10.3	4	20.0	15	11.8
Total	*107*	*100*	*20*	*100*	*127*	*100*

Table 15: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	n	%	n	%
Heroin	1	2.8	0	0
Methadone	2	5.6	0	0
Steroids	32	88.9	0	0
Unknown/Various	1	2.8	1	100
Total	*36*	*100*	*1*	*100*

Please Note: Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 16: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

	Heroin		Methadone		Steroids		Unknown/ Various	
Age Group	n	%	n	%	n	%	n	%
Under 18	0	0	0	0	0	0	0	0
18-19	0	0	0	0	6	100	0	0
20-24	0	0	1	9.1	10	90.9	0	0
25-29	0	0	0	0	9	100	0	0
30-34	0	0	0	0	2	100	0	0
35-39	1	20.0	0	0	3	60.0	1	20.0
40-44	0	0	1	33.3	1	33.3	1	33.3
45+	0	0	0	0	1	100	0	0
Total*	*1*	*2.7*	*2*	*5.4*	*32*	*86.5*	*2*	*5.4*

* % Totals are by Drug, not Age Group.

PHARMACY SYRINGE EXCHANGE

Table 17: Individuals by Gender

New Clients	n	%
Male	16	100
Female	0	0
Total	*16*	*100*
All Clients		
Male	44	97.8
Female	1	2.2
Total	*45*	*100*

Table 18: Individuals by Age Group

	New Clients		All Clients	
Age Group	**n**	**%**	**n**	**%**
Under 18	0	0	0	0
18-19	2	12.5	2	4.4
20-24	2	12.5	6	13.3
25-29	2	12.5	9	20.0
30-34	2	12.5	6	13.3
35-39	3	18.8	7	15.6
40-44	2	12.5	6	13.3
45+	3	18.8	9	20.0
Total	*16*	*100*	*45*	*100*

Table 19: Year to Date, by Gender & Age Group

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	**n**	**%**	**n**	**%**	***n***	**%**
Under 18	0	0	0	0	0	0
18-19	2	1.5	0	0	2	1.3
20-24	23	17.3	2	10.5	25	16.4
25-29	25	18.8	6	31.6	31	20.4
30-34	28	21.1	5	26.3	33	21.7
35-39	24	18.0	3	15.8	27	17.8
40-44	15	11.3	2	10.5	17	11.2
45+	16	12.0	1	5.3	17	11.2
Total	*133*	*100*	*19*	*100*	*152*	*100*

COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 20: Individuals in Syringe Exchange, by Gender

New Clients	n	%
Male	53	98.1
Female	1	1.9
Total	*54*	*100*
All Clients		
Male	205	94.9
Female	11	5.1
Total	*216*	*100*

Table 21: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted

New Clients	n	%
Male	6	85.7
Female	1	14.3
Total	*7*	*100*
All Clients		
Male	92	89.3
Female	11	10.7
Total	*103*	*100*

Table 22: Individuals in Syringe Exchange, by Age Group

	New Clients		All Clients	
Age Group	**n**	**%**	**n**	**%**
Under 18	0	0	0	0
18-19	8	14.8	8	3.7
20-24	13	24.1	43	19.9
25-29	11	20.4	44	20.4
30-34	4	7.4	32	14.8
35-39	9	16.7	40	18.5
40-44	5	9.3	28	13.0
45+	4	7.4	21	9.7
Total	*54*	*100*	*216*	*100*

Table 23: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	0	0	0	0
18-19	0	0	2	1.9
20-24	1	14.3	9	8.7
25-29	0	0	15	14.6
30-34	0	0	17	16.5
35-39	4	57.1	26	25.2
40-44	2	28.6	19	18.4
45+	0	0	15	14.6
Total	*7*	*100*	*103*	*100*

Table 24: Year to Date, by Gender & Age Group

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	**n**	**%**	**n**	**%**	***n***	***%***
Under 18	1	0.2	0	0	1	0.2
18-19	18	3.8	0	0	18	3.6
20-24	116	24.5	2	5.9	118	23.3
25-29	101	21.4	10	29.4	111	21.9
30-34	90	19.0	9	26.5	99	19.5
35-39	65	13.7	5	14.7	70	13.8
40-44	44	9.3	4	11.8	48	9.5
45+	38	8.0	4	11.8	42	8.3
Total	*473*	*100*	*34*	*100*	*507*	*100*

Table 25: Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	9,321	1,248	10,569	41,895
Needles	18,067	1,248	19,315	73,935

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)

Quarter 4 (2006/07)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 26: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	94	70.1
Female	40	29.9
Total	*134*	*100*
All Clients		
Male	626	69.8
Female	271	30.2
Total	*897*	*100*

Table 27: Year to Date, by Gender

New Clients	n	%
Male	280	69.5
Female	123	30.5
Total	*403*	*100*
All Clients		
Male	661	70.4
Female	278	29.6
Total	*939*	*100*

Table 28: Individuals in Contact with Treatment Services, by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	3	2.2	48	5.4
18-19	0	0	34	3.8
20-24	15	11.2	84	9.4
25-29	22	16.4	145	16.2
30-34	33	24.6	195	21.7
35-39	26	19.4	182	20.3
40-44	15	11.2	109	12.2
45+	20	14.9	100	11.1
Total	*134*	*100*	*897*	*100*

Table 29: Year to Date, by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	39	9.7	70	7.5
18-19	12	3.0	29	3.1
20-24	53	13.2	131	14.0
25-29	69	17.1	192	20.4
30-34	86	21.3	218	23.2
35-39	61	15.1	150	16.0
40-44	35	8.7	72	7.7
45+	48	11.9	77	8.2
Total	*403*	*100*	*939*	*100*

Table 30: Ethnicity of Individuals in Contact with Treatment Services

	New Clients		All Clients	
Ethnicity	**n**	**%**	**n**	**%**
White British	131	97.8	887	98.9
White Irish	1	0.8	2	0.2
Other White	0	0	2	0.2
White & Black Caribbean	0	0	1	0.1
White & Black African	0	0	1	0.1
Caribbean	1	0.8	2	0.2
Chinese	1	0.8	1	0.1
Unknown	0	0	1	0.1
Total	*134*	*100*	*897*	*100*

Table 31: Individuals in Contact with Treatment Services, by Main Drug of Use

	New Clients		All Clients	
Drug of Use	**n**	**%**	**n**	**%**
Heroin	44	32.8	362	40.4
Methadone	6	4.5	68	7.6
Other Opiates	3	2.2	17	1.9
Benzodiazepine	7	5.2	38	4.2
Amphetamines	5	3.7	40	4.5
Cocaine	15	11.2	99	11.0
Crack	9	6.7	36	4.0
Hallucinogens	0	0	1	0.1
Ecstasy	0	0	5	0.6
Cannabis	39	29.1	193	21.5
Antidepressants	3	2.2	5	0.6
Prescription Drugs	1	0.8	26	2.9
Other/Unknown	2	1.5	7	0.8
Total	*134*	*100*	*897*	*100*

CONNEXIONS

Quarter 4 (2006/07)

Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

Table 32: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	14	58.3
Female	10	41.7
Total	*24*	*100*

Table 33: Year to Date, by Gender

Gender	n	%
Male	20	58.8
Female	14	41.2
Total	*34*	*100*

Table 34: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	6	25.0
17	6	25.0
18	7	29.2
19	5	20.8
Total	*24*	*100*

Table 35: Year to Date, by Age

Age Group	n	%
16	6	17.6
17	12	35.3
18	8	23.5
19	8	23.5
Total	*34*	*100*

Table 36: Individuals in Contact with Connexions by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	4	16.7
Drugs	20	83.3
Total	*24*	*100*

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

Table 37: Year to Date, by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	8	23.5
Drugs	26	76.5
Total	*34*	*100*

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

COMBINED DATASETS

Quarter 4 (2006/07)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 38: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	**%**
Male	817	73.9
Female	288	26.1
Age Group		
Under 18	75	6.8
18-19	44	4.0
20-24	166	15.0
25-29	214	19.4
30-34	238	21.5
35-39	176	15.9
40-44	95	8.6
45+	97	8.8
Total	*1105*	*100*

Table 39: Year to Date, by Gender and Age Group

	Gender					
	Male		**Female**		***Total in Age Group***	
Age Group	**n**	**%**	**n**	**%**	***n***	***%***
Under 18	65	5.3	21	6.3	86	5.5
18-19	67	5.5	18	5.4	85	5.4
20-24	248	20.2	40	11.9	288	18.4
25-29	243	19.8	68	20.3	311	19.9
30-34	252	20.5	72	21.5	324	20.7
35-39	173	14.1	46	13.7	219	14.0
40-44	96	7.8	30	9.0	126	8.1
45+	84	6.8	40	11.9	124	7.9
Total	*1228*	*100*	*335*	*100*	*1563*	*100*

CROSS-MATCHED DATASETS

Quarter 4 (2006/07)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets



Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets